文献速递关节外科创伤骨科

采用作业成本法估算髋、膝关节假体周围感染治疗两年住院费用

Estimation of two-year hospital costs of hip and knee periprosthetic joint infection treatments using activity-based costing.
PubMed 文献 · Bone Joint J · 2024-10-01

基于澳大利亚和新西兰前瞻性观察队列,采用作业成本法估算273例髋和377例膝假体周围感染患者诊断后24个月内所有住院费用。髋、膝患者人均费用为64,585澳元(SD 53,550),单纯抗生素抑制治疗费用最低(髋20,296澳元、膝16,481澳元),二期翻修费用最高(髋113,226澳元、膝122,425澳元)。作者结论为假体周围感染治疗费用负担沉重,受治疗策略显著影响。

要点

  • 髋、膝假体周围感染患者诊断后24个月人均住院费用为64,585澳元(SD 53,550)。
  • 二期翻修费用最高:髋113,226澳元(SD 66,724)、膝122,425澳元(SD 60,874)。
  • 单纯抗生素抑制治疗费用最低:髋20,296澳元(SD 8,875)、膝16,481澳元(SD 6,712)。

核心结论

  • 假体周围感染治疗费用负担沉重,且受治疗策略显著影响。
  • 追加手术、更多诊疗次数和更长住院时间的治疗路径显著增加相关住院费用。
  • 对初始治疗以外的个体患者治疗路径进行前瞻性监测对量化假体周围感染治疗费用很重要。

研究设计与样本

  • 基于澳大利亚和新西兰前瞻性观察队列的入院和操作数据,为每例住院诊疗 episode 分配澳大利亚细化疾病相关组,采用作业成本法估算273例髋假体周围感染患者和377例膝假体周围感染患者的费用。
  • 费用汇总至诊断后24个月,以澳元表示。

主要发现

  • 髋、膝假体周围感染患者人均费用为64,585澳元(SD 53,550)。
  • 单期翻修髋、膝平均费用分别为67,029澳元(SD 47,116)和80,063澳元(SD 42,438)。
  • 二期翻修髋、膝平均费用分别为113,226澳元(SD 66,724)和122,425澳元(SD 60,874)。
  • 清创、抗生素和假体保留髋、膝平均费用分别为53,537澳元(SD 39,342)和48,463澳元(SD 33,179)。
  • 无手术管理的抗生素抑制治疗髋、膝平均费用分别为20,296澳元(SD 8,875)和16,481澳元(SD 6,712)。

关键数值与推荐

  • 髋假体周围感染患者有16种不同治疗路径,膝假体周围感染患者有18种治疗路径。
  • 追加治疗、诊疗次数和住院时间导致费用大幅增加,最高达369,948澳元。

临床怎么用

  • 作者指出,研究结果强调优化初始手术治疗的重要性,并使治疗医院了解为假体周围感染患者提供照护所需的资源。
  • 作者指出,量化假体周围感染治疗费用时,对初始治疗以外的个体患者治疗路径进行前瞻性监测很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Our aim was to estimate the total costs of all hospitalizations for treating periprosthetic joint infection (PJI) by main management strategy within 24 months post-diagnosis using activity-based costing. Additionally, we investigated the influence of individual PJI treatment pathways on hospital costs within the first 24 months. METHODS: Using admission and procedure data from a prospective observational cohort in Australia and New Zealand, Australian Refined Diagnosis Related Groups were assigned to each admitted patient episode of care for activity-based costing estimates of 273 hip PJI patients and 377 knee PJI patients. Costs were aggregated at 24 months post-diagnosis, and are presented in Australian dollars. RESULTS: The mean cost per hip and knee PJI patient was $64,585 (SD $53,550). Single-stage revision mean costs were $67,029 (SD $47,116) and $80,063 (SD $42,438) for hip and knee, respectively. Two-stage revision costs were $113,226 (SD $66,724) and $122,425 (SD $60,874) for hip and knee, respectively. Debridement, antibiotics, and implant retention in hips and knees mean costs were $53,537 (SD$ 39,342) and $48,463 (SD $33,179), respectively. Suppressive antibiotic therapy without surgical management mean costs were $20,296 (SD $8,875) for hip patients and $16,481 (SD $6,712) for knee patients. Hip patients had 16 different treatment pathways and knee patients had 18 treatment pathways. Additional treatment, episodes of care, and length of stay contributed to substantially increased costs up to a maximum of $369,948. CONCLUSION: Treating PJI incurs a substantial cost burden, which is substantially influenced by management strategy. With an annual PJI incidence of 3,900, the cost burden would be in excess of $250 million to the Australian healthcare system. Treatment pathways with additional surgery, more episodes of care, and a longer length of stay substantially increase the associated hospital costs. Prospectively monitoring individual patient treatment pathways beyond initial management is important when quantifying PJI treatment cost. Our study highlights the importance of optimizing initial surgical treatment, and informs treating hospitals of the resources required to provide care for PJI patients.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Hammat AS, Nelson R, Davis JS, et al. Estimation of two-year hospital costs of hip and knee periprosthetic joint infection treatments using activity-based costing. Bone Joint J. 2024. PMID: 39348903. doi:10.1302/0301-620X.106B10.BJJ-2024-0106.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。